HUYA was one of the first companies to recognize China's potential to help meet the global need for pre-clinical and clinical stage compounds for the drug development process. Leveraging the HUYA Integrated Co-Development Model for partnering with Chinese research institutions and pharmaceutical companies, HUYA identifies and licenses the most promising pre-clinical and clinical stage compounds in China. Through collaborations with its Chinese partners, the company provides a bridge to the global development process and biopharma market.
HUYA is the leader in global pharmaceutical co-development with China. With four strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA has pioneered the most innovative and productive approach to pharmaceutical co-development between the U.S. and China. HUYA has joint headquarter offices in San Diego, CA, and Shanghai. Additional information about the company is available at www.huyabio.com.
Guangzhou Institute of Biomedicine and Health (GIBH), as a branch of the Chinese Academy of Sciences, is a government-sponsored institution in China. It was established by the joint efforts of the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government, in accordance with the strategic demands for national socio-economic development and international trends in medicine and biopharmaceutical research. GIBH's focus is to become an internationally innovative and competitive R&D organization in the fields of biomedicine, vaccine development and diagnosis, fulfilling the responsibility of tackling key problems with innovation and integration of cutting-edge technologies as well as providing platforms for biomedical science.
|SOURCE HUYA Bioscience International|
Copyright©2009 PR Newswire.
All rights reserved